Harvey J. Alter

Harvey J. Alter
Born	Harvey James Alter 9/12/1935
Birthplace	New York City, New York, U.S.
Nationality	American
Occupation	Virologist, physician, medical researcher
Employer	National Institutes of Health
Known for	Discovery of the hepatitis C virus
Education	University of Rochester (BA, MD)
Awards	Karl Landsteiner Memorial Award (1992), Albert Lasker Award for Clinical Medical Research (2000), Nobel Prize in Physiology or Medicine (2020)

Harvey James Alter (born September 12, 1935) is an American virologist, physician, and medical researcher whose work fundamentally transformed the safety of the global blood supply and led to the identification of hepatitis C as a distinct viral disease. Over the course of a career spanning more than five decades at the National Institutes of Health (NIH), Alter demonstrated that the majority of post-transfusion hepatitis cases were caused by neither the hepatitis A nor hepatitis B virus, a finding that opened the path toward the eventual discovery and characterization of the hepatitis C virus. For this contribution, he was awarded the 2020 Nobel Prize in Physiology or Medicine, shared with Michael Houghton and Charles M. Rice. Alter served as chief of the infectious disease section and associate director for research of the Department of Transfusion Medicine at the Warren Grant Magnuson Clinical Center at the NIH in Bethesda, Maryland. His research made blood transfusion significantly safer for millions of patients worldwide and contributed to the development of screening tests that virtually eliminated transfusion-transmitted hepatitis in developed countries.

Early Life

Harvey James Alter was born on September 12, 1935, in New York City, New York. He grew up in a Jewish family in the city. Details about Alter's childhood and family background remain limited in publicly available sources, though he has spoken in interviews about his early interest in science and medicine. In a December 2020 interview conducted by the Nobel Prize organization, Alter reflected on his journey in science and the factors that shaped his career path.

Education

Alter attended the University of Rochester in Rochester, New York, where he earned his Bachelor of Arts degree in 1956. He continued his medical education at the University of Rochester School of Medicine and Dentistry, where he received his Doctor of Medicine degree. Alter was both an undergraduate and medical school alumnus of the university, making him one of the institution's most distinguished graduates. At the time of his Nobel Prize award, he was reported to be the 13th University of Rochester graduate or faculty member to receive a Nobel Prize.

Career

Early Career at NIH and Work with Baruch Blumberg

After completing his medical education, Alter joined the National Institutes of Health, where he would spend the vast majority of his professional career. At the NIH, he worked in the Department of Transfusion Medicine at the Warren Grant Magnuson Clinical Center. Early in his career at the NIH, Alter worked alongside Baruch Blumberg, who was investigating unusual antigens found in the blood of different populations. Their collaborative research contributed to the identification of the Australia antigen, which was subsequently recognized as a key component of the hepatitis B virus. Blumberg received the 1976 Nobel Prize in Physiology or Medicine in part for this discovery. Alter's involvement in the hepatitis B work gave him deep expertise in viral hepatitis and blood-borne infections, forming the foundation for the research that would define his career.

Discovery of Non-A, Non-B Hepatitis

In the mid-1970s, Alter turned his attention to a perplexing clinical problem. Despite the development of screening tests for hepatitis B virus in donated blood, a significant proportion of transfusion recipients continued to develop hepatitis after receiving blood products. This phenomenon suggested that another infectious agent, distinct from both hepatitis A and hepatitis B, was responsible for a large number of post-transfusion hepatitis cases.

Alter and his research team at the NIH Clinical Center undertook systematic studies of patients who developed hepatitis following blood transfusions. Through careful epidemiological and laboratory investigation, they demonstrated that the majority of these post-transfusion hepatitis cases could not be attributed to either the hepatitis A virus or the hepatitis B virus. The condition was initially designated "non-A, non-B hepatitis," a term that reflected the understanding that a new, as-yet-unidentified pathogen was involved.

Working independently but in parallel, Alter and Edward Tabor, a scientist at the U.S. Food and Drug Administration, conducted critical transmission studies using chimpanzees — the only non-human primates susceptible to hepatitis viruses. These experiments provided definitive proof that non-A, non-B hepatitis was caused by a transmissible agent and that this agent was likely a virus. By demonstrating that serum from patients with non-A, non-B hepatitis could transmit the disease to chimpanzees, Alter and Tabor established the infectious etiology of the condition and laid the groundwork for subsequent efforts to identify the specific viral pathogen.

The significance of Alter's work was substantial. At the time, post-transfusion hepatitis affected a considerable number of blood transfusion recipients and could lead to chronic liver disease, cirrhosis, and liver cancer. By demonstrating that a distinct, unidentified virus was responsible, Alter focused the attention of the global virology community on the need to find, characterize, and develop tests for this pathogen.

Identification of the Hepatitis C Virus

The identification of the specific virus responsible for non-A, non-B hepatitis proved to be an enormously challenging task. For more than a decade following Alter's initial characterization of the disease, the causative agent eluded researchers using conventional virological methods. The breakthrough came in 1989, when Michael Houghton and his colleagues at Chiron Corporation, using a novel molecular cloning approach, succeeded in identifying the viral genome. The newly identified pathogen was designated the hepatitis C virus (HCV).

Alter's contribution to this broader discovery was foundational. Without his demonstration that a distinct transmissible agent was responsible for non-A, non-B hepatitis, and without his establishment of the chimpanzee model for studying the disease, the subsequent molecular identification of HCV would not have been possible. Furthermore, after the virus was identified, Alter's group was among those that verified the discovery by demonstrating that the newly developed serological tests for HCV could detect the virus in stored blood samples from patients who had been diagnosed with non-A, non-B hepatitis.

The work of Charles M. Rice at Washington University in St. Louis further advanced the field by proving that hepatitis C virus alone could cause hepatitis, using a genetically engineered form of the virus. Together, the contributions of Alter, Houghton, and Rice constituted the complete arc from clinical observation of a new disease entity to molecular identification of the causative virus and definitive proof that it was the sole agent of disease.

Impact on Blood Safety

One of the most consequential outcomes of Alter's research was its impact on the safety of the blood supply. Before the identification of HCV and the development of screening tests, the risk of contracting hepatitis from a blood transfusion was estimated to be as high as 30 percent in some settings. The introduction of routine screening of donated blood for hepatitis C virus antibodies, made possible by the chain of discoveries initiated by Alter's work, reduced the risk of transfusion-transmitted hepatitis to near zero in countries that adopted the testing protocols.

The Nobel Assembly at Karolinska Institutet noted in its 2020 announcement that the work of Alter, Houghton, and Rice constituted "a decisive contribution to the fight against blood-borne hepatitis, a major global health problem that causes cirrhosis and liver cancer in people around the world." The discovery also enabled the development of direct-acting antiviral drugs that can now cure more than 95 percent of hepatitis C infections, transforming what was once a chronic and often fatal disease into a curable condition.

Positions at NIH

Throughout his career, Alter held several important positions at the NIH. He served as chief of the infectious disease section and as associate director for research of the Department of Transfusion Medicine at the Warren Grant Magnuson Clinical Center. The NIH Clinical Center, as the nation's largest hospital devoted entirely to clinical research, provided Alter with a unique environment in which to conduct his studies on transfusion-associated infections. His position allowed him to combine clinical observation with laboratory investigation, an approach that proved essential to identifying the problem of non-A, non-B hepatitis.

Alter was also an NIH intramural researcher, meaning his work was conducted within the NIH's own laboratories rather than through extramural grants. The NIH highlighted Alter's Nobel Prize as a significant achievement for its intramural research program.

Personal Life

Harvey J. Alter has maintained a relatively private personal life throughout his career. He is Jewish and was raised in New York City. In his December 2020 interview with the Nobel Prize organization, Alter discussed aspects of his life beyond the laboratory, including his perspectives on the scientific process and the role of mentorship in shaping young researchers. He has been based in the Washington, D.C., metropolitan area for most of his professional life, given his long tenure at the NIH in Bethesda, Maryland.

Recognition

Harvey J. Alter has received numerous awards and honors in recognition of his contributions to medical research and blood safety.

In 1992, Alter received the Karl Landsteiner Memorial Award, one of the most prestigious honors in the field of transfusion medicine, given by the American Association of Blood Banks.

In 2000, Alter was awarded the Albert Lasker Award for Clinical Medical Research, often considered the most prestigious biomedical research prize in the United States and sometimes referred to as "America's Nobel." The Lasker Award recognized his work in identifying the virus that causes hepatitis C and his contributions to the development of methods for screening blood donations.

Alter received the Distinguished Service Medal, which is the highest award conferred to civilians in United States government public health service, in recognition of his contributions to public health through his research on hepatitis.

In 2013, Alter was awarded the Canada Gairdner International Award, another major recognition of his work in medical science.

Alter is a member of the National Academy of Medicine (formerly the Institute of Medicine). The Academy noted his Nobel Prize as a recognition of one of its members.

The culmination of these recognitions came on October 5, 2020, when the Nobel Assembly at Karolinska Institutet announced that Alter, along with Michael Houghton and Charles M. Rice, had been awarded the 2020 Nobel Prize in Physiology or Medicine "for the discovery of Hepatitis C virus." The Nobel Committee emphasized that the laureates' work had made possible blood tests and new medicines that had saved millions of lives.

Legacy

Harvey J. Alter's legacy is most directly measured in the millions of lives saved through the transformation of blood transfusion safety that his research made possible. Before the identification of hepatitis C and the implementation of blood screening tests, transfusion-transmitted hepatitis was a common and feared complication of medical procedures requiring blood products. The chain of discoveries initiated by Alter's identification of non-A, non-B hepatitis ultimately led to the virtual elimination of this risk in developed countries and significantly reduced it worldwide.

The World Health Organization estimates that approximately 58 million people worldwide are chronically infected with the hepatitis C virus, and about 1.5 million new infections occur each year. Alter's work not only enabled the screening of blood supplies but also catalyzed research into antiviral therapies. The development of direct-acting antiviral agents, which can cure hepatitis C in the vast majority of patients, would not have been possible without the foundational work of identifying and characterizing the virus.

At the University of Rochester, Alter's Nobel Prize was celebrated as a point of institutional pride, with the university noting him as the 13th graduate or faculty member to receive the honor. His career at the NIH, spanning more than five decades, exemplifies the potential of sustained intramural government research to produce discoveries of global significance.

Alter's approach to science — characterized by meticulous clinical observation, systematic elimination of known causes, and persistence in the face of a problem that took more than a decade to fully resolve — has been cited as a model for translational medical research. His work demonstrates how clinical observations at the bedside can initiate a chain of discoveries that fundamentally changes medical practice and public health.

The recognition of Alter's contributions through the Nobel Prize in 2020 also highlighted the collaborative and cumulative nature of scientific discovery. While Alter identified the clinical problem and established the animal model, Michael Houghton achieved the molecular identification, and Charles M. Rice provided definitive proof of causation. Together, their work represents one of the most complete and consequential arcs in modern medical research.